# VEEV earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VEEV) · [Earnings tab](https://www.lopjlb.com/stock/VEEV?tab=earnings) Updated: 2026-08-26T05:27:10 Quarters analyzed: 8 ## Cross-quarter narrative Across 8 calls for VEEV, management tone moved from +0.80 (2025 Q2) to +0.80 (2027 Q1). Latest guidance stance: maintained. Latest desk line: Veeva beats Q1 guidance with $883M revenue, launches Falcon agentic AI platform targeting clinical document processing and safety cases, sees durable Crossix growth. ## Latest CallCard · Q1 Veeva beats Q1 guidance with $883M revenue, launches Falcon agentic AI platform targeting clinical document processing and safety cases, sees durable Crossix growth. **Guidance:** maintained — Q1 results ahead of guidance; full-year R&D guidance raised $5M; macro assumptions unchanged. **Tone:** mgmt 0.8 · Q&A pressure 0.4 · divergence 0.4 Management emphasizes strong execution, disruptive Falcon AI vision, and accretive new market. ### Demand visibility Strong Q1 across R&D and Crossix; Falcon pipeline building with Basics customers first. R&D products (eCOA, RTSM, EDC, Safety, LIMS) scaling early; Crossix benefiting from digital ad spend growth and product innovation; Falcon targeting high-volume repetitive work with standardized Basics customers as initial adopters. ### Margins / costs Non-GAAP operating margin ~44.7% in Q1; no detailed margin outlook provided. Revenue $883M, non-GAAP operating income $395M; no specific margin guidance discussed. ### Capital allocation No discussion of buybacks, dividends, or M&A. Capital allocation not addressed in prepared remarks or Q&A. ### Milestones - **Falcon agentic AI platform** [new]: Agentic labor platform targeting high-volume repetitive work in life sciences - **Falcon clinical document processing agents** [on_track]: Agents to collect, inspect, categorize clinical trial documents from research sites - **Falcon safety case processing agents** [on_track]: Agents for triage, categorization, and collection of safety cases - **Falcon regulatory correspondence agents** [on_track]: Agents for health authority correspondence processing - **Crossix measurement innovation** [on_track]: New channel measurement including OpenEvidence and Meta driving market share gains - **R&D product scaling (eCOA, RTSM, EDC, Safety, LIMS)** [on_track]: Early lifecycle products scaling but still early in adoption curve - **Veeva Basics Falcon adoption** [new]: Standardized Basics customers targeted as first Falcon adopters due to uniform configuration - **MAAP architecture (Models, Agents, Applications)** [on_track]: New technical architecture integrating models, agents, and applications ### Fears / risks - **Macro uncertainty**: Macro environment unchanged but pockets of strength/weakness; guidance assumes no significant changes. - **Falcon execution risk**: New agentic labor platform unproven at scale; requires headless application operation and change management. - **Falcon adoption risk**: Enterprise customers may require adaptive agents and testing phases; adoption timeline uncertain. - **Falcon pricing uncertainty**: Pricing model not finalized; likely per document or per case. - **Crossix customer concentration**: GLP-1 exposure noted but diversified across measurements, audiences, and indications. - **Cannibalization concern**: Analysts questioned if Falcon could cannibalize existing SaaS revenue; management says accretive. - **Competitive pressure**: AI agent space competitive; Veeva's structural advantage cited but not guaranteed. - **Change management**: Consulting needed for agent adoption; industry standardization required. ### Key quotes > “We had a strong start to the year, delivering results ahead of our guidance. Total revenue in the quarter was $883 million with non-GAAP operating income of $395 million.” — Peter Gassner > “Falcon specifically is at the agent layer and that's agentic labor. So fully replacing parts -- jobs that people used to do.” > “We're trying to simplify and standardize and integrate the tech of the development area of life sciences. That's not anything that anybody asked us for, right? That's the vision that we have, and that's not anything that anybody has tried” > “I think overall, what we see in the macro is an environment that is unchanged from when we gave guidance a few months ago.” — Brian Van Wagener > “Definitely all accretive because this is not a market we address today. We don't play in that market today. This is not type of labor or work that we supply. So it's definitely going to be accretive.” — Peter Gassner ## Quarter one-liners - **2027 Q1:** Veeva beats Q1 guidance with $883M revenue, launches Falcon agentic AI platform targeting clinical document processing and safety cases, sees durable Crossix growth. - **2026 Q4:** Veeva posted a strong Q4 2026 with revenue $836M, beat guidance, highlighted AI‑driven automation, CRM add‑on growth, Crossix momentum and top‑20 Vault CRM migrations, while noting guidance remains unchanged and AI impact is early. - **2026 Q3:** Veeva reports strong Q3 ($811M revenue, $365M non-GAAP op income), highlights AI progress and Vault CRM migration (14/20 top customers), with CRM now ~20% of revenue; clinical pipeline strong, AI agents rolling out across apps through 2026. - **2026 Q2:** Veeva beats Q2 guidance ($789M revenue), resolves decade-long IQVIA dispute unlocking commercial cloud, raises full-year billings guide $35M, advances Veeva AI platform with agents but sees no material revenue until post-FY27. - **2026 Q1:** Veeva beats Q1 guidance with $759M revenue, achieves $3B run-rate; Vault CRM on track for 200 live customers, Crossix >30% growth drives commercial acceleration; horizontal CRM targeting first customers by year-end; margins expected to normalize to 44%. - **2025 Q4:** — - **2025 Q3:** Veeva beats Q3 guidance ($699M revenue, $304M non-GAAP operating income); Vault CRM re-platforming live with full functionality; Development Cloud adoption broad; visibility marginally improved vs year ago. - **2025 Q2:** Veeva Q2 beats guidance with $676M revenue; Vault CRM winning 14 deals, Service Center launched, CTMS adoption strong, R&D subscription guide raised on better pipeline visibility. ## Theme arcs - **Management tone** (stable): Δ mgmt=+0.00 ## Fear persistence - **cro adoption** [resolved]: 2025 Q2 - **billing volatility** [resolved]: 2025 Q2 - **r&d subscription guidance volatility** [resolved]: 2025 Q2 - **unified platform vision adoption** [resolved]: 2025 Q2 - **migration timeline dependency** [resolved]: 2025 Q2 - **competitive clinical landscape** [resolved]: 2025 Q2 - **regulatory policy uncertainty** [resolved]: 2025 Q3 - **large-customer migration complexity** [resolved]: 2025 Q3 - **clinical trial volume fluctuations** [resolved]: 2025 Q3 - **mlr bot monetization uncertainty** [resolved]: 2025 Q3 ## Guidance path 2025 Q2:raised → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:raised → 2026 Q3:maintained → 2026 Q4:maintained → 2027 Q1:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/VEEV`